Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2016 - 2023)

Historic Non-Current Deffered Revenue for Theravance Biopharma (TBPH) over the last 11 years, with Q3 2023 value amounting to $175000.0.

  • Theravance Biopharma's Non-Current Deffered Revenue fell 1206.03% to $175000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $175000.0, marking a year-over-year decrease of 1206.03%. This contributed to the annual value of $192000.0 for FY2022, which is 3806.45% down from last year.
  • According to the latest figures from Q3 2023, Theravance Biopharma's Non-Current Deffered Revenue is $175000.0, which was down 1206.03% from $181000.0 recorded in Q2 2023.
  • In the past 5 years, Theravance Biopharma's Non-Current Deffered Revenue registered a high of $21.7 million during Q1 2019, and its lowest value of $175000.0 during Q3 2023.
  • For the 5-year period, Theravance Biopharma's Non-Current Deffered Revenue averaged around $3.7 million, with its median value being $329000.0 (2021).
  • Data for Theravance Biopharma's Non-Current Deffered Revenue shows a peak YoY increase of 1091.95% (in 2021) and a maximum YoY decrease of 9601.69% (in 2021) over the last 5 years.
  • Over the past 5 years, Theravance Biopharma's Non-Current Deffered Revenue (Quarter) stood at $6.8 million in 2019, then crashed by 94.85% to $348000.0 in 2020, then dropped by 10.92% to $310000.0 in 2021, then crashed by 38.06% to $192000.0 in 2022, then fell by 8.85% to $175000.0 in 2023.
  • Its last three reported values are $175000.0 in Q3 2023, $181000.0 for Q2 2023, and $187000.0 during Q1 2023.